Compare RA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RA | ARVN |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | 1260 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.6M | 806.0M |
| IPO Year | N/A | 2018 |
| Metric | RA | ARVN |
|---|---|---|
| Price | $12.91 | $12.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 23 |
| Target Price | N/A | ★ $17.80 |
| AVG Volume (30 Days) | 280.8K | ★ 2.3M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 14.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $312,300,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 93.86 |
| 52 Week Low | $11.89 | $5.90 |
| 52 Week High | $17.32 | $22.48 |
| Indicator | RA | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 38.74 | 55.73 |
| Support Level | $13.06 | $12.47 |
| Resistance Level | $13.24 | $13.56 |
| Average True Range (ATR) | 0.08 | 0.56 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 12.50 | 40.00 |
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities. The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.